MET ‐amplified gastric cancers exhibit co‐amplifications of BRAF , CDK6 , and EGFR
The Journal of Pathology: Clinical Research · 2026-07 · 12 (4)
DOI: 10.1002/2056-4538.70104 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, online erschienen am 08.07.2026. Verfasst von Silke Lüschen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany. Hauptthemen laut MEDLINE: Stomach Neoplasms, Proto-Oncogene Proteins c-met, Gene Amplification, Proto-Oncogene Proteins B-raf. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
MET‐positive gastric cancer (GC) has a poor prognosis. In addition, targeting MET with monoclonal antibodies or tyrosine kinase inhibitors had limited success. We searched for additional genetic alterations that might explain the poor outcome of MET‐positive GC and lack of response to MET‐targeted therapies. Multiregional whole‐exome sequencing was performed on primary tumor and lymph node metastasis samples from two MET ‐amplified discovery cases. Immunohistochemistry, in situ hybridization, and digital droplet polymerase chain reaction were performed in a validation cohort of 24 MET ‐amplified GCs. Whole‐exome sequencing found 191 and 166 non‐synonymous mutations, respectively. Only eight genes showed non‐synonymous mutations in both cases, including TP53 . Copy number variations (CNVs) were found in 18 and 14 autosomes, respectively, most commonly affecting chromosome 7. Since BRAF , CDK6 , and EGFR are also localized on chromosome 7, validation studies were performed by fluorescence or chromogenic in situ hybridization, and co‐amplification was found in 54% of the cases, including two discovery and 24 validation cases. Different combinations were found, for example, CDK6 + MET , EGFR + MET , CDK6 + EGFR + MET , BRAF + CDK6 + EGFR + MET , or BRAF + EGFR + MET . A database search using cBioPortal confirmed our findings. However, marked intra‐ and intertumoral heterogeneity was observed, and CNVs were highly variable and spatially separated. MET amplification in GC is accompanied by amplification of other oncogenes located on chromosome 7, that is, BRAF , CDK6 , and EGFR , in a highly heterogeneous manner leading to substantial intra‐ and intertumoral heterogeneity. This may cause diagnostic and therapeutic challenges, provoke subclonal evolution, and lead to poor prognosis of MET ‐amplified GC and the failure of targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany.
- Department of Cancer Genomics, Avera Cancer Institute, Sioux Falls, SD, USA.
- Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Internal Medicine II, Hematology and Oncology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany.
- Department of General Surgery, Visceral, Thoracic, Transplantation and Pediatric Surgery, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany.
- Institute for Clinical Molecular Biology, Christian-Albrechts-University, Kiel, Germany.
ORCID-Profile: Sandra Krüger, Dita Ulase, Anu Amallraja, Philip Rosenstiel, Tobias Meißner, Christoph Röcken
Förderung
- NCI NIH HHS
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Lüschen, S., Ebert, U., Behrens, H. M., Krüger, S., Ulase, D., Amallraja, A., Heckl, S. M., Becker, T., Rosenstiel, P., Meißner, T., & Röcken, C. (2026). MET ‐amplified gastric cancers exhibit co‐amplifications of BRAF , CDK6 , and EGFR. The Journal of Pathology: Clinical Research, 12(4). https://doi.org/10.1002/2056-4538.70104
Vancouver
Lüschen S, Ebert U, Behrens HM, Krüger S, Ulase D, Amallraja A, et al. MET ‐amplified gastric cancers exhibit co‐amplifications of BRAF , CDK6 , and EGFR. The Journal of Pathology: Clinical Research. 2026;12(4). doi:10.1002/2056-4538.70104
BibTeX
@article{Lschen2026,
author = {Lüschen, Silke and Ebert, Ulrike and Behrens, Hans-Michael and Krüger, Sandra and Ulase, Dita and Amallraja, Anu and Heckl, Steffen M and Becker, Thomas and Rosenstiel, Philip and Meißner, Tobias and Röcken, Christoph},
title = {MET ‐amplified gastric cancers exhibit co‐amplifications of BRAF , CDK6 , and EGFR},
journal = {The Journal of Pathology: Clinical Research},
year = {2026},
volume = {12},
number = {4},
doi = {10.1002/2056-4538.70104}
}
EUVIMED